NNMT Inhibition
in Laboratory Research:
A Review of 5-Amino-1MQ Studies
A plain-language summary of published preclinical research on nicotinamide N-methyltransferase (NNMT) inhibition using 5-amino-1-methylquinolinium — covering published animal study dose ranges, the SAM–NAD⁺ mechanism, muscle and metabolic findings, and comparison with NMN, NR, and related research compounds
Results observed in animal models do not establish that equivalent effects will occur in humans. This content does not make any claim that 5-Amino-1MQ prevents, treats, or cures any disease or health condition in humans. 5-Amino-1MQ is supplied by Union Biolabs strictly as a research compound for laboratory use only. It is not a medicine, not approved for human use, and not intended for self-administration. This article is intended for researchers and scientists reviewing the published literature.
This article summarises published preclinical research on 5-amino-1-methylquinolinium (5-Amino-1MQ), a small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT). The literature reviewed spans in vitro adipocyte studies, diet-induced obesity mouse models, aged skeletal muscle models, gut microbiome analyses, and observational human data on NNMT expression. All efficacy findings are derived exclusively from animal and cell-based experimental systems. No human interventional trial data on 5-Amino-1MQ exists in the published literature as of June 2026. This review presents the science accurately, contextualises what the animal findings mean and do not mean, and identifies the significant translational uncertainty that remains before any human application could be considered.
Background: What Is 5-Amino-1MQ?
5-Amino-1MQ is the common shorthand for 5-amino-1-methylquinolinium, a synthetic small molecule developed through systematic medicinal chemistry research at the University of Texas Health Science Center. It was identified through a structure-activity relationship programme designed to find selective, membrane-permeable inhibitors of the enzyme nicotinamide N-methyltransferase (NNMT).
The compound is characterised by high aqueous solubility and the ability to pass through cell membranes — important properties for a molecule whose target operates inside cells. In laboratory pharmacokinetic studies conducted in rats, it demonstrates measurable systemic exposure after administration and a favourable stability profile in liver tissue across multiple species.
It is classified as a research chemical. It has not been evaluated by any regulatory body (FDA, MHRA, EMA) for use in humans. It is not a licensed medicine in any jurisdiction.
In the research literature, 5-Amino-1MQ is also referenced by the abbreviations NNMTi (NNMT inhibitor) and occasionally as 5-MQ, 5A-1MQ, or 5-amino 1MQ. Its CAS number is 1005-39-6. Researchers searching for this compound in databases may also encounter its IUPAC name: 5-amino-1-methylquinolin-1-ium.
Research context: All characterisation of 5-Amino-1MQ described in this article derives from laboratory studies. No regulatory authority has assessed this compound for human safety or efficacy.Mechanism of Action: The NNMT–SAM–NAD⁺ Pathway
Published research describes 5-Amino-1MQ as a selective inhibitor of NNMT — an enzyme that catalyses the methylation of nicotinamide to form 1-methylnicotinamide (1-MNA), consuming S-adenosylmethionine (SAM) as a methyl donor in the process.
In the peer-reviewed literature, this reaction is described as having two downstream biochemical consequences in experimental cell models. First, it depletes SAM — the cell's principal methyl donor — which in adipocyte models has been associated with altered gene expression patterns related to lipid metabolism. Second, it diverts nicotinamide away from the salvage pathway that produces nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in cellular energy metabolism and redox reactions.
In vitro studies report that 5-Amino-1MQ inhibits NNMT with an IC50 of approximately 1.2 μM — approximately ten times more potent than the parent compound 1-methylquinolinium — and does not significantly inhibit related SAM-dependent methyltransferases at concentrations producing NNMT inhibition, indicating selectivity in cell-based assays.
Research context: Selectivity data are from in vitro assays. Whether equivalent selectivity is maintained at physiologically relevant concentrations in a living organism, particularly in humans, has not been established.NNMT Expression in Human Studies: Observational Evidence
While no interventional human trials of 5-Amino-1MQ exist, a separate body of observational research has characterised NNMT enzyme expression in human tissue samples. This research concerns the enzyme itself — not 5-Amino-1MQ — and is relevant as background context for understanding why NNMT has attracted research interest as a potential target.
3.1 — Kannt et al. (2015, Diabetologia)
This observational study measured NNMT messenger RNA expression in white adipose tissue biopsies and plasma 1-MNA concentrations in 314 human participants. The study found that higher NNMT gene expression in adipose tissue was statistically associated with measures of insulin resistance in participants with type 2 diabetes. The study also observed that interventions known to improve insulin sensitivity — structured exercise and bariatric surgery — were associated with reductions in adipose NNMT expression in the same participants.
Research context: This is an observational association study. It demonstrates a statistical relationship between NNMT expression and metabolic measures in human tissue — it does not establish that inhibiting NNMT with any compound produces equivalent effects in humans. Association is not causation, and the relationship between NNMT and metabolic outcomes in humans is not fully understood.Design: Cross-sectional observational study of NNMT mRNA in WAT biopsies · Participants: 314 (surgical patients, exercise cohort, bariatric surgery cohort)
Reported Finding: Higher adipose NNMT expression statistically associated with insulin resistance markers. Exercise and bariatric surgery interventions associated with lower adipose NNMT expression in study participants.
Limitation: Observational design. Cannot establish causality. Does not involve 5-Amino-1MQ. Does not demonstrate that NNMT inhibition by any pharmacological means produces metabolic changes in humans.
3.2 — Genetic Association Research
Published genetic and epigenetic studies (Bañales-Luna et al., 2020, Scientific Reports; Crujeiras et al., 2018, Molecular Nutrition and Food Research) have identified statistical associations between genetic variants near NNMT-related loci and metabolic phenotypes in human cohorts, and have described epigenetic signatures linked to NNMT gene expression in human adipose tissue. These findings are cited in the literature as context for why NNMT has been proposed as a research target. They do not constitute evidence that 5-Amino-1MQ or any NNMT inhibitor has effects in humans.
Research context: Genetic association and epigenetic studies identify statistical relationships at a population level. They do not demonstrate that pharmacological NNMT inhibition produces any specific outcome in humans.Metabolic Research in Animal Models
4.1 — Neelakantan et al. (2018, Biochemical Pharmacology)
The foundational in vivo study on 5-Amino-1MQ was published by Neelakantan, Watowich, and colleagues at the University of Texas. Diet-induced obese C57BL/6 mice received 5-Amino-1MQ at 20 mg/kg by subcutaneous injection three times daily over 11 days (n = 9 per group). Compared to vehicle-treated control animals on the same diet, treated mice showed statistically significant reductions in body weight and white adipose tissue mass. Adipocyte size was reduced under histological examination. Food intake was not significantly different between groups.
The authors concluded that selective NNMT inhibition was sufficient to produce measurable metabolic changes in this mouse model of diet-induced obesity, and that these changes occurred independently of altered food consumption in the experimental system studied.
Research context: This study was conducted entirely in mice over 11 days with 9 animals per group. Diet-induced obesity in inbred mouse strains is a laboratory model that does not replicate human metabolic disease. Results from this model have not been reproduced in human subjects. The study duration, sample size, and species are all significant limitations on any translational inference.Species: C57BL/6 diet-induced obese mice · n: 9/group · Duration: 11 days · Route: Subcutaneous injection
Reported Findings: Significant reduction in body weight and white adipose mass vs vehicle control (p<0.05). Reduced adipocyte size on histology. No significant difference in food intake between groups.
Limitations: Very small n (9/group). Extremely short duration (11 days). Inbred mouse model only. No human data. Results cannot be extrapolated to predict human outcomes.
4.2 — Sampson, Dimet et al. (2021, Scientific Reports)
A subsequent study examined 5-Amino-1MQ in combination with dietary modification in diet-induced obese mice (n = 6–8 per group). Animals were transitioned from a high-fat diet to a low-fat diet, either with or without concurrent 5-Amino-1MQ administration, for approximately seven weeks. The group receiving both dietary change and compound showed statistically significant reductions in body weight (p < 0.0001) and fat mass (p < 0.0001) compared to high-fat diet controls, with end-of-study measures in the combination group that were statistically similar to those of lean control animals maintained on a low-fat diet throughout. The dietary change alone group showed intermediate outcomes. Secondary endpoints included measures of hepatic fat content, which also showed statistically significant differences in the combination group.
Research context: Small sample sizes (6–8 mice per group). Mouse model only. Combination interventions in animal models cannot be directly modelled onto human physiology. The "lean control" comparison is within-study and within-species only.Species: DIO mice · n: 6–8/group · Duration: ~7 weeks
Reported Findings: Body weight reduction p<0.0001; fat mass reduction p<0.0001 in combination group vs high-fat control. Liver fat (lobe fat p=0.0034; total liver weight p=0.0011; microvesicular steatosis p=0.0425; macrovesicular steatosis p=0.0039) also significantly different in combination group vs dietary change alone.
Limitations: Very small n (6–8/group). Mouse model only. Combined intervention (diet + compound) makes it difficult to attribute effects to compound alone. No human data.
Skeletal Muscle Research in Animal Models
A separate line of published research has examined the effects of NNMT inhibition on skeletal muscle function in aged mouse models. This work has been motivated by observations that NNMT expression appears elevated in aged rodent muscle tissue compared to young tissue, and that this elevation has been associated with altered muscle stem cell (satellite cell) behaviour in experimental systems.
5.1 — Neelakantan et al. (2019, Biochemical Pharmacology)
This study used an aged mouse muscle injury model to examine whether NNMT inhibition affected the behaviour of satellite cells — the stem cells responsible for muscle repair — and the histological characteristics of muscle after injury. Aged mice treated with 5-Amino-1MQ showed greater satellite cell activation and proliferation in response to induced muscle injury compared to untreated aged controls, and post-injury muscle fibre cross-sectional area was larger in the treated group.
Research context: Aged mouse muscle injury model only. Satellite cell biology in inbred aged mice does not fully replicate human sarcopenia or age-related muscle decline. These findings have not been reproduced in human subjects.Species: Aged C57BL/6 mice · Model: Induced muscle injury
Reported Findings: Greater satellite cell activation and fusion in 5-Amino-1MQ-treated aged mice vs untreated aged controls following induced muscle injury. Larger post-injury muscle fibre cross-sectional area in treated group.
Limitations: Mouse model only. Aged inbred mice are an experimental approximation of age-related muscle change, not a clinical model. No human data.
5.2 — Dimet-Wiley et al. (2024, Scientific Reports)
The most recently published study on 5-Amino-1MQ examined grip strength and voluntary running distance in aged mice assigned to four groups: sedentary without treatment, sedentary with 5-Amino-1MQ, a progressive exercise protocol without treatment, and progressive exercise combined with 5-Amino-1MQ treatment. Grip strength was measured at study end. Sedentary animals receiving the compound showed approximately 40% greater grip strength than untreated sedentary controls. Animals in the exercise-only group showed approximately 20% greater grip strength than untreated sedentary controls. Animals receiving both exercise and the compound showed approximately 60% greater grip strength than untreated sedentary controls. Running distance on a voluntary wheel was also greater and more sustained in the compound-plus-exercise group compared to exercise alone.
Research context: Aged mouse study only. Grip strength in mice is measured by a standardised rodent apparatus and is not directly comparable to human muscle strength assessments. Voluntary wheel running in mice reflects a species-specific behaviour. These findings have not been reproduced in any human study.Species: Aged C57BL/6 mice · Protocol: PoWeR progressive exercise ± 5-Amino-1MQ treatment · n: Multiple groups
Reported Findings: Compound-treated sedentary mice: ~40% greater grip strength vs sedentary control. Exercise alone: ~20% greater. Combined: ~60% greater. Running distance more sustained in combined group. Proteome and metabolome analyses completed.
Limitations: Animal study only. Grip strength and wheel running are species-specific measures. No human data. Proteome and metabolome findings require independent replication.
Liver and Gut Microbiome Findings in Animal Models
6.1 — Hepatic Findings (Sampson, Dimet et al. 2021)
Secondary endpoints of the 2021 dietary intervention mouse study included measures of hepatic fat content assessed histologically. Statistically significant differences in liver lobe fat, total liver weight, and two forms of hepatic steatosis (microvesicular and macrovesicular) were observed between the compound-plus-diet group and the diet-only group. The authors noted this as a secondary observation within a body weight and body composition study.
Research context: Histological liver findings in mice only. Mouse liver biology and human liver disease pathophysiology are not equivalent. These observations do not constitute evidence that 5-Amino-1MQ prevents or treats any liver condition in humans.6.2 — Gut Microbiome (Dimet, Wu et al. 2022, Scientific Reports)
A 2022 study examined cecal microbiome composition in diet-induced obese mice following dietary change with or without 5-Amino-1MQ treatment. The microbiome profiles of combination-treated mice were reported to be statistically similar to those of lean control animals maintained on a low-fat diet throughout, while diet-change-alone animals showed intermediate profiles. The authors described this as an exploratory finding and noted that correlations between microbiome composition and metabolic outcomes in this model were limited.
Research context: Mouse gut microbiome data only. Rodent gut microbiome composition is not equivalent to human gut microbiome composition. This is an exploratory, hypothesis-generating observation in an animal model.Species: DIO mice · n: 6–8/group · Endpoint: Cecal microbiome 16S sequencing
Reported Finding: Microbiome profiles in combination group statistically similar to lean controls; diet-alone group intermediate. Authors classified as exploratory.
Limitations: Very small n. Mouse microbiome. Exploratory endpoint. Authors note limited correlations between microbiome and metabolic outcomes within the study.
Preclinical Dose Ranges Used in Published Animal Studies
Researchers reviewing the 5-Amino-1MQ literature frequently need to know what doses were used in published experiments in order to compare methodology, design replication studies, or understand the pharmacological context of reported findings. The following is a factual compilation of dose ranges drawn directly from the peer-reviewed literature.
| Published Study | Species / Model | Dose Reported | Route | Duration |
|---|---|---|---|---|
| Neelakantan et al. 2018 (Biochem Pharmacol) | C57BL/6 DIO mice | 20 mg/kg × 3 daily | Subcutaneous (SC) | 11 days |
| Sampson, Dimet et al. 2021 (Sci Rep) | DIO mice + lean diet intervention | NNMTi (dose per study protocol) | Subcutaneous (SC) | ~7 weeks |
| Dimet, Wu et al. 2022 (Sci Rep) | DIO mice + dietary change | NNMTi (dose per study protocol) | Subcutaneous (SC) | ~7 weeks |
| Dimet-Wiley et al. 2024 (Sci Rep) | Aged C57BL/6 mice ± PoWeR exercise | NNMTi (dose per study protocol) | Subcutaneous (SC) | 8 weeks |
| Neelakantan et al. 2019 (Biochem Pharmacol) | Aged C57BL/6 mice — muscle injury model | NNMTi (dose per study protocol) | Subcutaneous (SC) | Post-injury period |
In Vitro Concentrations in Published Cell Studies
Published in vitro studies on 5-Amino-1MQ in adipocyte cell cultures report using the compound at concentrations ranging from 0.5 μM to 10 μM, with the IC50 for NNMT inhibition established at approximately 1.2 μM (Neelakantan et al., 2018). Selectivity studies tested concentrations up to 10 μM against related SAM-dependent methyltransferases.
For cell culture reconstitution, published methodology describes aqueous vehicle preparation. Lyophilised 5-Amino-1MQ is highly water-soluble, consistent with its physicochemical profile described in the medicinal chemistry literature.
Research context: In vitro concentrations and reconstitution information are provided for researchers designing preclinical cell-based experiments consistent with the published literature. These concentrations have no relevance to any human administration context.How the Pivotal Dose Was Selected: The Structure-Activity Relationship Study
The dose used in the founding in vivo study (20 mg/kg) was selected based on prior pharmacokinetic and dose-ranging work described in the structure-activity relationship (SAR) paper (Neelakantan et al., J Med Chem 2017) and subsequent unpublished dose-finding experiments referenced in the 2018 paper. The SAR study characterised over a dozen quinolinium analogs before identifying 5-Amino-1MQ as the lead compound based on its IC50, selectivity profile, membrane permeability, and aqueous solubility.
Research context: Dose selection rationale is provided as context for researchers understanding the preclinical methodology. The dose used in a mouse study to achieve biological effect is not a guide for any other use.How 5-Amino-1MQ Compares to Related Compounds in the Research Literature
Researchers investigating 5-Amino-1MQ frequently require comparative context — particularly how it relates to other compounds that interact with the NAD+ pathway, the methylation cycle, or NNMT inhibition. The following is drawn entirely from published peer-reviewed sources.
8.1 — 5-Amino-1MQ vs NMN and NR: Same Pathway, Different Entry Points
Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the most widely studied NAD+ precursor compounds. They are structurally and mechanistically distinct from 5-Amino-1MQ, despite acting on the same pathway.
NMN and NR work by supplying additional substrate: they are converted into NAD+ through the salvage pathway, raising the cellular NAD+ pool by adding to it. 5-Amino-1MQ works by reducing drain on the existing pool: by blocking NNMT, it prevents nicotinamide from being methylated to 1-MNA and diverted away from NAD+ synthesis. A useful experimental analogy used in the published literature is a bathtub: NMN and NR turn up the tap; 5-Amino-1MQ plugs the drain.
5-Amino-1MQ additionally affects the SAM methylation axis — preserving S-adenosylmethionine for gene-regulatory methylation reactions — which NMN and NR do not. This mechanistic distinction is one reason 5-Amino-1MQ has been proposed in published reviews as potentially complementary to rather than interchangeable with NAD+ precursors in research contexts.
Critically, NMN and NR have substantially more published human trial data than 5-Amino-1MQ. Multiple human trials of NMN and NR have been completed and published; no human trial of 5-Amino-1MQ has been completed as of June 2026.
Research context: Mechanistic comparison does not imply clinical equivalence or interchangeability. NMN and NR have human safety data; 5-Amino-1MQ does not. This comparison is a factual summary of published mechanistic literature only.8.2 — 5-Amino-1MQ vs JBSNF-000088: Related NNMT Inhibitors
JBSNF-000088 is a structurally distinct NNMT inhibitor developed by Sanofi, also studied in diet-induced obesity mouse models (Kannt et al., Nature Communications 2018). Published data for JBSNF-000088 in mice showed reduced body weight, improved insulin sensitivity, and normalised glucose tolerance in HFD models — findings in the same direction as those reported for 5-Amino-1MQ. JBSNF-000088 uses a different chemical scaffold (a substrate analogue mechanism) compared to 5-Amino-1MQ's nicotinamide-competitive approach. Neither compound has published human efficacy data.
8.3 — 5-Amino-1MQ vs 1-MQ: The Parent Compound
1-MQ (1-methylquinolinium) is the parent compound from which 5-Amino-1MQ was derived. The introduction of an amino group at the C5 position of the quinolinium ring increased NNMT inhibitory potency approximately tenfold — from an IC50 of approximately 12 μM for 1-MQ to approximately 1.2 μM for 5-Amino-1MQ in published SAR assays. 5-Amino-1MQ also demonstrated superior membrane permeability and selectivity versus related methyltransferases compared to the parent compound in the same study.
8.4 — 5-Amino-1MQ and Metformin: AMPK Pathway Overlap
Published reviews on NNMT inhibition note that both 5-Amino-1MQ (via NAD+ and SAM effects on metabolic gene regulation) and metformin (directly) activate AMPK downstream in experimental models. This mechanistic overlap has been discussed in the literature as one reason NNMT inhibition produces metabolic effects superficially similar to those of AMPK activators. However, 5-Amino-1MQ and metformin are structurally unrelated and act through entirely different primary mechanisms. Metformin has decades of human clinical data; 5-Amino-1MQ has none. They are not equivalent and should not be described as interchangeable.
Research context: Downstream AMPK pathway overlap is a mechanistic observation from the literature. It does not imply equivalent clinical outcomes or safety profiles. Metformin is a licensed medicine; 5-Amino-1MQ is a research compound.8.5 — Comparison Table: Published Literature Features
| Feature | 5-Amino-1MQ | NMN | NR | JBSNF-000088 |
|---|---|---|---|---|
| Compound class | Small molecule (methylquinolinium) | Nucleotide precursor | Nucleoside precursor | Small molecule (substrate analogue) |
| Primary target | NNMT (direct inhibition) | NAD+ salvage pathway (substrate) | NAD+ salvage pathway (substrate) | NNMT (substrate analogue) |
| NAD+ effect (preclinical) | ↑ intracellular NAD+ (preserves pool) | ↑ NAD+ (adds to pool) | ↑ NAD+ (adds to pool) | ↑ NAD+ (preserves pool) |
| SAM pathway effect | Yes — preserves SAM | No | No | Yes — preserves SAM |
| Tissue specificity | High (adipose/liver in obesity models) | Systemic | Systemic | Adipose/liver (mouse models) |
| Anti-obesity evidence | ⚠ Animal only | Weak / mixed (human) | Weak / mixed (human) | ⚠ Animal only |
| Published human trial data | None | Multiple completed trials | Multiple completed trials | None published |
| IC50 for primary target | ~1.2 μM (NNMT, in vitro) | N/A (substrate) | N/A (substrate) | ~1.8 μM (NNMT, in vitro) |
Preclinical Safety Data
Published animal studies on 5-Amino-1MQ have reported no observable gross toxicity, adverse behavioural changes, or organ pathology in the treated mouse groups studied. Food intake was not significantly altered in treated animals, and no significant off-target enzyme inhibition was detected in selectivity assays conducted in vitro.
Pharmacokinetic data from rat plasma studies (Awosemo et al., 2021) confirmed systemic exposure after administration and characterised the compound's absorption and stability profile in rat plasma — data relevant to planning future preclinical dose-ranging studies.
The following table summarises what the published preclinical literature does and does not address regarding safety.
| Safety Parameter | Preclinical Evidence | Human Safety Evidence |
|---|---|---|
| Acute toxicity (short-term) | No toxicity observed in short-term mouse studies | None — no human data |
| Food intake / appetite effects | No significant effect observed in mouse studies | None — no human data |
| In vitro selectivity | High selectivity vs related enzymes in cell assays | None — no human data |
| Liver enzyme effects | Not specifically reported in published studies | None — no human data |
| Chronic / long-term safety | Not studied beyond ~7 weeks in any published study | None — no human data |
| Cardiovascular effects | Not specifically evaluated in published studies | None — no human data |
| Reproductive / developmental | Not evaluated in published literature | None — no human data |
| IND-enabling toxicology | Not publicly reported | Prerequisite for any human trial |
Translational Limitations: What the Research Does Not Show
The published literature on 5-Amino-1MQ reflects a scientifically coherent and mechanistically plausible research programme. However, it is important to be precise about what the available evidence establishes and what it does not.
What the published research shows: That 5-Amino-1MQ inhibits NNMT in cell assays at approximately 1.2 μM; that it produces measurable metabolic changes in small groups of diet-induced obese inbred mice over short experimental durations; that aged mice receiving the compound showed greater grip strength and satellite cell activity in the experimental conditions studied; and that no obvious toxicity was reported in these animal studies.
What the published research does not show: Any effect — beneficial or otherwise — in human beings. Human metabolic disease is substantially more complex than mouse models. Multiple compounds that produced strong results in diet-induced obesity mouse models have failed to demonstrate equivalent efficacy in human clinical trials. The translation rate from mouse metabolic data to human clinical benefit is historically low in this field.
"The history of metabolic drug research contains many compounds that reversed obesity in mice and produced no equivalent effect when tested in humans. The preclinical data on 5-Amino-1MQ is scientifically interesting, but it is not evidence of human efficacy."
Additionally, the animal studies reviewed used inbred mouse strains on artificially high-fat diets — a model that does not replicate the genetic diversity, comorbidities, or environmental complexity of human metabolic disease. Sample sizes were small (n = 6–9 per group), durations were short (11 days to 7 weeks), and none of the studies included the safety endpoints required by regulators before human testing can begin.
Research Timeline: Published Studies to Date
Complete Study Register
Structure-activity relationship characterisation of quinolinium scaffold. IC50 = 1.2 μM. Confirmed selectivity vs related methyltransferases. Established medicinal chemistry basis for subsequent in vivo studies.
n=314. NNMT expression in WAT biopsies statistically associated with insulin resistance. Exercise and bariatric surgery associated with reduced NNMT expression. Observational only. Does not involve 5-Amino-1MQ.
Genetic association study. NNMT-related variants associated with BMI and resting energy expenditure in a population cohort. Does not involve 5-Amino-1MQ.
Epigenetic patterns in human adipose tissue statistically associated with NNMT gene expression. Observational. Does not involve 5-Amino-1MQ.
C57BL/6 DIO mice · n=9/group · 11 days SC injection · Significant body weight and adipose mass reduction vs control (p<0.05) · No change in food intake · MOUSE DATA ONLY
DIO mice · n=6–8/group · ~7 weeks · Body weight (p<0.0001) and fat mass (p<0.0001) significantly lower in combination group · Secondary liver histology findings · MOUSE DATA ONLY
Aged C57BL/6 mice · Induced muscle injury model · Greater satellite cell activation and larger post-injury fibre CSA in treated group · MOUSE DATA ONLY
Aged C57BL/6 mice · 4-group design · Grip strength differences reported: sedentary+compound ~40%, exercise alone ~20%, combined ~60% vs untreated sedentary · Running distance findings · Proteome/metabolome analyses · MOUSE DATA ONLY
DIO mice · n=6–8/group · Cecal microbiome 16S sequencing · Combination group profile similar to lean controls · Authors classified as exploratory · MOUSE DATA ONLY
Validated analytical method for plasma quantification in rats. Systemic exposure confirmed. Oral bioavailability characterised. Preclinical pharmacokinetic groundwork for potential future IND-enabling studies.
No completed or results-reported Phase 1, 2, or 3 human clinical trials on 5-Amino-1MQ have been published as of June 2026. Early-stage translational interest and some trial registrations have been reported, but no human safety or efficacy data is available in the peer-reviewed literature.
References
- Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141–152.
- Neelakantan H et al. Small molecule NNMT inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochem Pharmacol. 2019;163:481–492.
- Neelakantan H et al. Structure-activity relationship for small molecule inhibitors of NNMT. J Med Chem. 2017.
- Sampson MN, Dimet AL et al. Combined NNMT inhibition and reduced-calorie diet normalizes body composition in obese mice. Sci Rep. 2021.
- Dimet AL, Wu QL et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice. Sci Rep. 2022;12(1).
- Dimet-Wiley AL, Latham CM et al. NNMT inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Sci Rep. 2024;14:15554.
- Kannt A, Pfenninger A et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue with insulin resistance. Diabetologia. 2015.
- Awosemo O et al. Development and validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma. J Pharm Biomed Anal. 2021.
- Liu Y et al. Roles of nicotinamide N-methyltransferase in obesity and type 2 diabetes. BioMed Res Int. 2021;9924314.
- Zhang Z et al. NNMT as a therapeutic target for non-alcoholic fatty liver disease. Arch Biochem Biophys. 2025.
- Sun Y et al. NNMT as a novel therapeutic target for metabolic syndrome. Front Pharmacol. 2024.
Full Legal & Research Disclaimer
Nature of this content: This article is a summary of published peer-reviewed scientific literature. It is written for researchers and scientists reviewing the academic evidence base on NNMT inhibition. It does not constitute medical advice, health guidance, or a product recommendation.Evidence limitations: All efficacy findings described in this article are derived from animal (mouse) studies and in vitro cell experiments. No human clinical trial data on 5-Amino-1MQ has been published. Animal model findings do not establish that equivalent effects occur in humans. The translational gap between preclinical metabolic data and human clinical outcomes is well documented and historically significant.
Product status: 5-Amino-1MQ is supplied by Union Biolabs exclusively as a research compound for qualified laboratory use only. It is not a medicine. It has not been approved or licensed by the MHRA, FDA, EMA, or any other regulatory body for any therapeutic purpose. It is not intended for human consumption, self-administration, or use outside a controlled laboratory research setting.
No therapeutic claims: Nothing in this article constitutes a claim that 5-Amino-1MQ prevents, treats, cures, or mitigates any disease or health condition in humans. Researchers are responsible for compliance with all applicable regulations governing the use of research compounds in their jurisdiction.
© 2026 Union Biolabs · unionbiolabs.com · For laboratory research use only.